SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Adaptive Biotechnologies announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.
(Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO)
“We are delighted to work so closely with Janssen to further elucidate the role that immune profiling can play in scientific research and drug development,” said Chad Robins, CEO and Founder of Adaptive Biotechnologies. “Adaptive’s corporate focus is to further understand the immune response in patients living with diseases like cancer and autoimmune disorders.”
Adaptive’s CEO Robins will be sharing this corporate focus on immune profiling to improve patient care during the upcoming JP Morgan Healthcare conference in San Francisco on January 15, 2014. Details on Adaptive’s full suite of research and diagnostic immunosequencing assays, as well as other key partnerships, will be presented.
About Adaptive
Adaptive Biotechnologies Corporation (“Adaptive” or the “Company”) is a pioneer in immunosequencing diagnostics, with a focus in oncology. The Company leverages advances in next generation sequencing (“NGS”) to profile T-Cell and B-Cell Receptors (“TCRs” and “BCRs”). This patented breakthrough enables in-depth characterization of the immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and monitoring of cancer patients. The Company’s first clinical application, clonoSEQTM, is for monitoring Minimal Residual Disease (“MRD”) in blood-based cancers. The Company recently launched clonoSEQTM as a CLIA certified Laboratory Developed Test (“LDT”) in the second quarter of 2013. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care. Adaptive is currently validating additional oncology diagnostics to quantify the presence and clonality of Tumor Infiltrating Lymphocytes (“TIL”) and to create a reliable measure of “immunocompetency” to predict or monitor response to cancer treatments that directly alter the host immune system. Adaptive incubates and validates potential clinical products by offering fee-for-service access to its proprietary immune profiling sequencing technology under the brand name immunoSEQTM.
SOURCE Adaptive Biotechnologies Corporation
Help employers find you! Check out all the jobs and post your resume.
